Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet

[PR Newswire] – WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ — Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: … more

View todays social media effects on AMGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Amgen is hiring next, click here to view